Surgery Partners (SGRY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting will be held virtually on June 6, 2025, with voting on four key proposals, including director elections, executive compensation, a new incentive plan, and auditor ratification.
Shareholders of record as of April 8, 2025, are eligible to vote, with materials available online and by request.
The Board recommends voting in favor of all proposals and emphasizes the importance of shareholder participation.
Voting matters and shareholder proposals
Proposals include electing three Class I directors for three-year terms, an advisory vote on executive compensation, approval of the 2025 Omnibus Incentive Plan, and ratification of Ernst & Young LLP as the independent auditor.
The Board unanimously recommends voting FOR all proposals.
Voting can be done online, by phone, or by mail, and shareholders can change their vote at the meeting.
Board of directors and corporate governance
The Board is divided into three classes with staggered three-year terms; 11 directors currently serve.
Director independence is reviewed per Nasdaq standards; most directors are independent.
Committees include Audit, Compensation, Nominating and Corporate Governance, and Compliance and Ethics, each with defined charters and responsibilities.
Directors are expected to attend all meetings; in 2024, all met attendance requirements.
Latest events from Surgery Partners
- Payer mix shifts and cost actions drive a conservative outlook and portfolio optimization.SGRY
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - 2025 margin pressure and net loss shape a cautious 2026 outlook with $530M EBITDA guidance.SGRY
Q4 20253 Mar 2026 - Q2 revenue up 14.2%, Adjusted EBITDA up 18.1%, and 2024 guidance raised on strong growth.SGRY
Q2 20242 Feb 2026 - Q3 revenue and EBITDA grew double digits, led by high acuity cases and acquisitions.SGRY
Q3 202415 Jan 2026 - 2024 revenue up 13.5% and Adjusted EBITDA up 16%, with strong 2025 growth outlook.SGRY
Q4 202415 Dec 2025 - Virtual annual meeting on June 6, 2025, with board-backed votes on directors, pay, plan, and auditor.SGRY
Proxy Filing2 Dec 2025 - Q2 2025 revenue and EBITDA rose sharply, guidance reaffirmed, and leverage reduction prioritized.SGRY
Q2 202523 Nov 2025 - Q1 2025 revenue up 8.2% to $776M, Adjusted EBITDA rose, and guidance was reaffirmed.SGRY
Q1 202517 Nov 2025 - Q3 2025 revenue grew 6.6% to $821.5M, with higher EBITDA but a net loss of $22.7M.SGRY
Q3 202511 Nov 2025